PLIVA d.d. (ZSE: PLVA-R-A), a subsidiary of Barr Pharmaceuticals, Inc. ("Barr"), today reported financial results for the six month period ended 30 June 2008, prepared in accordance with International Financial Reporting Standards (IFRS).
Read more ...
The Medicines Company Reports First Quarter 2008 Financial Results
The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008. Financial highlights for the first quarter of 2008:
Net revenue increased by 19% to $79.4 million for the first quarter of 2008 from $66.6 million for the first quarter of 2007.
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and twelve months ended December 31, 2007. Onyx reported a net loss of $11.7 million, or $0.21 per share, for the fourth quarter of 2007 compared to a net loss of $20.7 million, or $0.47 per share, in the same period in the prior year.
Read more ...
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to US$44 million, comprising an upfront fee and development milestones, plus royalties on future sales.
Read more ...
The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results
The Medicines Company (NASDAQ: MDCO) today announced its financial results for the full year and fourth quarter of 2007. Financial highlights for the full year of 2007:
Net revenue increased by 20% to $257.5 million for 2007 from $214.0 million for 2006.
Teva to acquire CoGenesys with a purchase price of $400 million cash
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that it has entered into a definitive agreement to acquire CoGenesys, Inc., a privately-held biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories.
Read more ...
Merz Group experiences successful 2006/07 financial year
Merz GmbH & Co. KGaA, based in Frankfurt am Main, was able to continue the dynamic growth of the previous years during their 2006/07 financial year (ending June 30th). Group revenue increased by 12.8% to 535.5 million Euros (previous year: 474.6 million Euros) due to new product introductions and internationally successful marketing and sales measures.
Read more ...
PLIVA d.d. (ZSE: PLVA-R-A), a subsidiary of Barr Pharmaceuticals, Inc. ("Barr"), today reported financial results for the six month period ended 30 June 2008, prepared in accordance with International Financial Reporting Standards (IFRS). 
The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008. Financial highlights for the first quarter of 2008:
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that it has entered into a definitive agreement to acquire CoGenesys, Inc., a privately-held biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories. 
Merz GmbH & Co. KGaA, based in Frankfurt am Main, was able to continue the dynamic growth of the previous years during their 2006/07 financial year (ending June 30th). Group revenue increased by 12.8% to 535.5 million Euros (previous year: 474.6 million Euros) due to new product introductions and internationally successful marketing and sales measures.